Amy Ko - Concepedia

Author

Amy Ko

Brigham and Women's Hospital ORCID

Also Known As

A Ko, A. H. Ko, A. Ko, ALVIN KO, Amy Ko, Ardenne Ko

Publications

954

Citations

H-Index

Concepts

All Affiliations

Brigham and Women's Hospital Harvard University Broad Institute Dana-Farber Cancer Institute University of Pittsburgh Medical Center

About

Amy Ko is an author at Brigham and Women's Hospital specializing in medicine, cancer therapeutics, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	128
2	Public Health	1	1	35
3	Biology	1	1	35
4	Endocrinology	1	1	35
5	Molecular Genetics	1	1	35

Amy Ko

Publications

867

Citations

H-Index

Page 1

	Year	Citations
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation Shannon Elf, Nouran S. Abdelfattah, Edwin Chen, Cancer Discovery	2016	272
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms Edwin Chen, Rebekka K. Schneider, Lawrence J. Breyfogle, Blood	2014	97
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN Shannon Elf, Nouran S. Abdelfattah, April J. Baral, Blood	2017	88
Incidence of Varicose Veins, Chronic Venous Insufficiency, and Progression of the Disease in the Bonn Vein Study II Eberhard Rabe, Felizitas Pannier, Amy Ko, Journal of Vascular Surgery	2010	55
Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors Alan P. Venook, Amy Ko, Margaret A. Tempero, Journal of Clinical Oncology Progressive Neuroendocrine TumorsPathologyPharmacotherapyTumor BiologyNeuro-oncology	2008	52
Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice Markus Bender, Silvia Giannini, Renata Grozovsky, Blood	2014	45
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment Corey J. Langer, Vera Hirsh, Amy Ko, Clinical Lung Cancer First-line TherapyUrologyOncologyMedicineCancer Management	2014	41
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes Vera Hirsh, Amy Ko, Richard Pilot, Clinical Lung Cancer	2016	36
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Trials	2015	36
The POU Factor Ventral Veins Lacking/Drifter Directs the Timing of Metamorphosis through Ecdysteroid and Juvenile Hormone Signaling CeCe Cheng, Amy Ko, Leila Chaieb, PLoS Genetics Comparative EndocrinologyGeneticsEntomologyMolecular GeneticsReproductive Biology	2014	35

Page 1